Summary
Intracellular SMAD proteins mediate signal transduction of the Transforming Growth Factor-(TGF-) superfamily that play pleiotropic roles in hematopoietic development, suggesting that intracellular Smad proteins may play key roles in hematopoietic regulation. Although inhibitory Smad7, which negatively regulates TGF-signaling, has been implicated in the development of mature hematopoietic cells, a role for Smad7 in regulating more primitive hematopoietic cells has yet to be examined. Here, Smad7 was over-expressed in primary human SCID repopulating cells (SRC), representing a common myeloid/lymphoid precursor cell with the functional capacity to repopulate the bone marrow of NOD/SCID recipient mice. Retroviral transduction of Smad7 into human umbilical cord blood (CB)-SRC caused a shift from lymphoid dominant engraftment toward increased myeloid contribution, and increased the myeloidcommitted clonogenic progenitor frequency in reconstituted mice. Neither myeloid nor B-lymphoid lineage developmental stages were compromised by Smad7 overexpression, suggesting Smad7 regulates cell fate commitment decisions of myeloid/lymphoid precursors by augmenting myeloid differentiation at the expense of lymphoid commitment. In addition, global gene expression analysis using microarray was used to identify potential target genes regulated by SMAD7 in primitive hematopoietic cells that may control this process. Our study demonstrates a novel and unexpected role for Smad7 in modulating the cell fate decisions of primary multipotent human repopulating cells and establishes a role for Smad7 in the development of primitive human hematopoietic cells.
Introduction
The Transforming Growth Factor-(TGF-) superfamily of extracellular ligands, including the TGFs, Activins, and Bone Morphogenetic Proteins (BMPs), are responsible for mediating a wide array of cellular responses ranging from proliferation and differentiation to embryonic patterning [1] [2] [3] . Multiple TGFfamily ligands are involved in embryonic and adult hematopoietic development. TGF-is best characterized as negative regulator of primitive hematopoietic cells 4, 5 , while BMP-4 is involved in the induction of hematopoietic tissue from embryonic mesoderm 6, 7 , and has also been shown to enhance the survival and proliferation of human hematopoietic stem cells following ex vivo culture 8, 9 .
Ligands of the TGF-superfamily interact with their cognate type I and type II serine-threonine kinase receptors at the cell surface, and transmit signals through members of the SMAD family of intracellular signal transducers. Receptor-regulated Smads (R-Smads) signal downstream of TGF-and Activin (Smad2 and 3), or BMP (Smad1, 5 and 8), through receptor-mediated R-Smad phosphorylation, association with Smad4, and nuclear translocation followed by modulation of TGF-responsive gene expression 1, [10] [11] [12] . In contrast, the Inhibitory Smads (I-Smads; Smad6 and Smad7) antagonize TGF-/RSmad signal transduction by preventing R-Smad activation at the receptor level and also affect BMPs [13] [14] [15] [16] .
Given the importance of multiple TGF-ligands in hematopoiesis, it is likely that their intracellular mediators, the Smads, also play key roles in hematopoietic regulation. Smad7 primarily functions as an intracellular antagonist of TGF-mediated signaling 14, 15 , wherein signaling through TGF-family receptors causes upregulation of Smad7 15, 17, 18 and through a stable association with activated type I TGF-(T RI), BMP and Activin receptors 14, 15, 19, 20 blocks activation of R-Smads.
Smad7 transcription is also induced in response to signaling by various ligands upstream of NF-B (22) (23) (24) and Jak1-Stat1 21 pathways, and in response to various physiological stimuli 17, 22, 23 . A few lines of evidence converge to suggest that Smad7 may be an important hematopoietic regulator. Smad7 is capable For personal use only. at PENN STATE UNIVERSITY on March 1, 2013. bloodjournal.hematologylibrary.org From of antagonizing Activin-induced erythroid differentiation in a murine erythroleukemia cell line 24 , and inhibits TGF-mediated growth arrest in murine B-lymphocytes 18, 25 and primary activated murine T-lymphocytes 26 . During early hematopoietic development of Xenopus embryos, Smad7 mRNA expression, similar to that of the globin transcripts, is progressively restricted to ventral mesoderm and embryonic blood islands, suggesting that Smad7 is important in early hematopoiesis 27 . Very recently, Smad7 was identified as a gene enriched in populations of murine embryonic stem cells (ESC) and murine and human hematopoietic stem cells (HSC) through screening of oligonucleotide microarrays 28, 29 . Taken together, this evidence suggests that in addition to its role in mature hematopoietic cells, Smad7 might play a role in primitive hematopoietic cells with multipotent potential.
To understand the biological role of Smad7 in primitive human hematopoiesis, we have used a retroviral gene transfer approach to examine the effect of Smad7 on candidate human HSCs capable of repopulating the bone marrow (BM) of nonobese diabetic severe combined immunodeficient (NOD/SCID) mice 30, 31 . In comparison with control vector transduced SRC, Smad7 SRC exhibited a shift from a Blymphoid dominant graft, toward a graft with a higher frequency of myeloid progeny within the murine bone marrow (BM). This phenotypic increase in myeloid progeny was coupled with a higher frequency of functional clonogenic myeloid progenitors isolated from the mouse BM. Our data suggests that Smad7 is capable of altering the balance of cell fate commitment decisions within human SRC, which represent a common lymphoid/myeloid precursor cell with in vivo repopulating function. This study identifies a novel role for Smad7 in cell fate commitment decisions in primary human multipotent cells. 
Materials and Methods
Reverse Transcription PCR Analysis mRNA was extracted from purified cells using an mRNA extraction kit, and was reverse transcribed into cDNA using a first strand cDNA synthesis kit, according to the manufacturer's instructions (Amersham Pharmacia). RT-PCR reactions were used to detect Smad7 and -glucuronidase transcripts using a PerkinElmer 9700 cycler, under the following PCR conditions: an initial 2min denaturation at 96°C, followed by 40 cycles of 45 sec denaturation at 94°C, 45 sec annealing at 60°C, and 2 min extension at 72°C, followed by a final extension at 72°C for 10min. Primer sequences used for amplification of 307 bp Smad7 transcripts were forward 5'-CCA TCA CCT TAG CCG ACT CT-3' and reverse 5'-GCA AAA GCC ATT CCC CTG AG- 
Retroviral Vectors
A BamHI linker was subcloned into the HpaI-SnaBI sites of the MIEV vector 32 (a kind gift from Robert Hawley). A 2.9 kb EcoRI-BamHI fragment coding for the full length human Smad7 gene 14 (from pCMV5-Smad7, a kind gift from Jeffrey Wrana), was subcloned into the EcoRI-BamHI sites of the modified MIEV vector, upstream of an internal ribosomal entry site (IRES) and an enhanced green fluorescent protein (GFP) reporter gene, as previously described 33 .
Retroviral Packaging Lines
The bicistronic Smad7 vector, and control MIEV vector, were transfected into the amphotrophic PA317 packaging line 34 using Fugene6 (Roche). Transient retroviral supernatant was harvested, supplemented with 8 µg/mL polybrene (Sigma), and used to infect the GaLV-pseudotyped PG13 packaging line 35 33 .
Retroviral transduction of human hematopoietic cell lines
Human megakaryocytic leukemia lines MBA.1 36 and M-O7e 37 were grown in IMDM with 10% FBS and 100 units/mL GM-CSF (M-O7e only). For transduction with Smad7 or Vector retroviruses, cells were resuspended once in 0.45 µm filtered virus-containing supernatants, collected in IMDM with 10% FBS and 300 units/mL GM-CSF, and supplemented with 8 ng/mL polybrene. Two days after retroviral transduction, cultured cells were washed with PBS, and GFP+ cells were selected by fluorescence activated cell sorting, for subsequent expansion in the culture conditions described above.
Assessment of Smad7 overexpression in retrovirally transduced cells
PG13 packaging lines and MBA.1 cells transduced with Vector or Smad7 retrovirus, sorted for GFP+ expression, were analyzed by Western blotting for detection of Smad7 protein. Cell lysates were prepared using lysis buffer containing 10% Triton, IM Tris, 0.5M EDTA and protease inhibitors Leupeptin and Aprotinin at 10mg/ml, and proteins were separated using 15% SDS-PAGE and transferred to nitrocellulose membrane. Equal amount of protein was loaded per lane in all experiments as determined by comassi staining of parallel gels used for subsequent Western blotting. Smad7 protein was detected using the Smad7 antibody H-79 (Santa Cruz Biotechnologies, Inc.), a goat-anti rabbit-HRP 2 o antibody (Santa Cruz Biotechnologies, Inc.) and enhanced chemiluminescence system (ECL, Amersham Pharmacia) and Kodak X-omat film. 
TGF-1 Growth Inhibition Assay

Human cell purification
Samples of full term human umbilical cord blood (CB) were obtained in conjunction with local ethical and biohazard authorities of the University of Western Ontario and London Heath Sciences Centre. CB samples were diluted 1:3 in PBS, and mononuclear cells (MNCs) were collected by separation on Ficollpaque (Pharmacia). Contaminating red blood cells were lysed with a 0.8% ammonium chloride solution.
Lineage depleted (Lin-) cells were purified by negative selection using a StemSep device (StemCell Technologies) as previously described 38 . Cells expressing lineage commitment markers (Lin+) were separately eluted from the column for use as accessory cells during transplantation 39 . CB Lin-and Lin+ populations were cryopreserved in fetal bovine serum (FBS) and 10% DMSO, and stored in liquid nitrogen. 
Production of retrovirus conditioned supernatants
Analysis of clonogenic progenitors from NOD/SCID mice
In mice with sufficient levels of engraftment and retroviral marking, clonogenic progenitors arising from transduced SRC were assessed in semi-solid methylcellulose culture. Mouse BM cells were sorted on a FACSVantage SE, and primitive human cells expressing the transgene were isolated based on the phenotype CD45+CD34+GFP+. As a control, CD45+CD34+GFP-cells were also isolated from the same For personal use only. at PENN STATE UNIVERSITY on March 1, 2013. bloodjournal.hematologylibrary.org From mice. In some instances, cells were also selected based on exclusion of the 7-AAD-viability dye. 5000 CD45+CD34+GFP+ or GFP-cells were placed into Methocult H4320 (Stem Cell Technologies) supplemented with the following recombinant human cytokines: 50 ng/mL SCF, 10 ng/mL GM-CSF, 10 ng/mL IL-3, and 3 units/mL erythropoietin (epo), and maintained at 37 o C with 5% CO2 in a humidified atmosphere. Expression of the GFP transgene was assessed by fluorescence microscopy after 7 days, and differential colony counts were performed according to standard protocols, after 14 days.
Quantitative polymerase chain reaction (Q-PCR)
Expression of Smad7 (forward primer: 5 AGAAGGTGCGGAGCAAAAT3
and reverse: GGCATGGACTGTGGTCA TGAC 3 and the 2 -ct equation 43 was used to calculate the relative expression of Smad7.
Amplification of RNA for microarray analysis
The MessageAmp aRNA kit (Ambion, USA) was used for RNA amplification as described elsewhere 44 .
Briefly, total RNA, extracted from transgenic Smad7 and vector cells, was used as the starting material for generating aRNA. First strand cDNAs were synthesized using poly dT primers followed by 2 nd strand cDNA synthesis. The double stranded cDNA was used as a template for in vitro transcription (IVT) reaction to generate aRNA. Biotin-16-UTP (Roche Diagnostics; Canada) and Biotin-11-CTP (Perkin Elmer; USA) nucleotides were incorporated to the newly synthesized RNA during IVT reaction. The quality and quantity of aRNA were evaluated with a spectrophotometer (Fisher Scientific, USA) and with an Agilent bioanalyzer (Agilent Technologies, USA) at the London Regional Genomic Center (LRGC; Robarts Research Institute, London Ontario, Canada)
Microarray Analysis
Human HG-U133A chips (Affymetrix Co., USA) were used for hybridization reactions. Probe preparations, hybridization, washing and data acquisition were performed at the LRGC (London Ontario, Canada)
according to standard protocol provided by Affymetrix (Affymetrix Co., USA). The quality of array experiments was primarily evaluated by looking at the number of present and absent calls and the ratio of signal intensity of 3 to 5 end of house keeping genes such as GAPDH and -Actin. The GeneSpring6.0 software (GeneSpring Co. USA) was used for data analysis such as normalization and clustering. The data were normalized per chip and per gene using algorithms in GeneSpring6.0. For per chip normalization, data in each chip was normalized to the 50 th percentile of the measurements taken from that chip. Per gene normalization was done by dividing the mean signal intensity from each gene in the Smad7 transgenic cell sample to the mean of the same gene in the vector control. Genes that were significantly (P<0.05) differentially (more than two times) regulated and flag present in at least one of the replicates were considered as differentially expressed in Smad7 transgenic cells.
Statistical analysis
Values shown represent the mean + SEM for n number of experiments. Statistical analyses were performed using a 2-tailed, paired student's T-test. Results were reported as significant if p < 0.05. 
Results
De novo expression of Smad7 in human hematopoietic tissues, construction and evaluation of Smad7 retroviral vector
To determine whether Smad7 might regulate TGF-/BMP signaling pathways in primitive human hematopoietic cells, we have examined various human fetal blood (FB) and CB populations by reverse transcriptase-polymerase chain reaction (RT-PCR) analysis for Smad7 expression (Fig 1a) . Smad7 mRNA was expressed in the FB and CB Lin-CD34+CD38-cell populations known to be enriched for primitive (Fig 1b) . In Lin-CD34+CD38-CB cells, SMAD7 was expressed at greater than 2-fold the level in Lin-CD34+CD38+ cells (Fig 1b) suggesting the Smad7 may play in role in primitive repopulating stem cells. Furthermore, expression of Smad7 was regulated among differentiated hematopoietic cells, and was preferentially expressed among the myeloid subsets indicated, with low levels of expression in cells within the B-cell lineage (Fig 1c) . These data indicate that expression of Smad7 is tightly regulated during human hematopoiesis, and suggests that Smad7 may be involved in regulating the process of human hematopoietic differentiation.
To examine the biological role of Smad7 in human hematopoiesis, retroviral gene transfer was used to overexpress Smad7 in putative human hematopoietic stem cells, defined functionally by their ability to repopulate the bone marrow of NOD/SCID mice with human hematopoietic cells of multiple committed 45, 46 .The human Smad7 gene was subcloned upstream of an enhanced green fluorescent protein (GFP) reporter to create a bicistronic retroviral vector for Smad7 overexpression (Fig 1d) . Stable GaLVpseudotyped retroviral producer lines expressing the Smad7 and control Vector retroviruses were constructed as described 33 . The GFP-selected producer lines were confirmed to produce infectious retrovirus by transduction of the human megakaryocytic leukemia cell lines MBA.1 36 and M-O7e 37 . PG13-Smad7, MBA.1-Smad7, and M-O7e-Smad7 GFP+ cell lines were morphologically indistinguishable from their Vector control counterparts (Fig 1e, and data not shown) , suggesting that Smad7 did not alter cellular morphology in stably transduced cells. Western blot analysis of GFP+ PG13-Smad7 and MBA.1-Smad7 cell lysates demonstrated an approximate 2-fold increase in Smad7 protein compared to endogenous levels of Smad7 protein detected in PG13-Vector and MBA.1-Vector cells, respectively (Fig 1f) . In addition, Smad7 was expressed at approximate 2-3-fold greater levels in HeLa-Smad7 and M-O7e-Smad7 compared to HeLa-Vector and M-O7e Vector cells, respectively, as detected using amplified RNA (Fig 1g, and data not shown). These results indicate that transduction of Smad7 causes an increase in both Smad7 mRNA and protein in transduced cells.
The M-O7e megakaryocytic cell line has previously been shown to be sensitive to TGF-1 mediated growth inhibition 47 . To determine if the retrovirally produced Smad7 was capable of inhibiting TGF-signaling, M-O7e cells overexpressing Smad7 protein were cultured in a TGF-growth inhibition assay in the presence of 0 and 1 ng/mL TGF-1. Regardless of TGF-treatment, M-O7e-Smad7 cells demonstrated a higher rate of proliferation than M-O7e-Vector cells, suggesting an effect of Smad7 on endogenous secreted TGF- (Fig 1h, inset) . Both M-O7e-Smad7 and M-O7e-Vector cells exhibited growth inhibition in the presence of TGF- (Fig 1h, inset) 
by TGF-, whereas M-O7e-Vector showed a 25% reduction in proliferation (Fig 1h) . This higher proliferative rate and abrogation of TGF-mediated growth inhibition in the day 2 TGF-culture of M-O7e suggests that the Smad7 protein overexpressed in these cells can inhibit TGF-signaling. Interestingly, increased cellular proliferation in the absence of exogenous TGF-ligand was also observed in activated mature splenic T-cells derived from mice engineered to misexpress Smad7 by means of a T-cell specific promoter 26 , supporting our observation that Smad7 overexpression is functional.
Ex vivo transduction of Smad7 into primitive human hematopoietic cells
The CB Lin-cells used in this study are enriched for primitive hematopoietic cells with in vitro progenitor and in vivo repopulating function, present mostly within the CD34+CD38-subfraction 30 , and have been shown to express Smad7 mRNA (Fig 1b) . Efficiency of myeloid and B-cell lineage depletion is shown in a representative example of CB MNCs before and after lineage depletion using CD33 and CD15 for myeloid cells and CD19 and CD20 for B-lymphoid cells (Fig. 2a) . 
remained primitive based on retention of CD34 expression, regardless of the vector treatment (Fig 2d) , suggesting that Smad7 did not enhance or inhibit the differentiation of the transduced Lin-cells in vitro. In addition, cells transduced with Smad7 vs. Vector alone demonstrated a greater than 3-fold increase in expression of Smad7 (Fig 2e) , thereby supporting effective Smad7 overexpression in transgenic human hematopoietic cells to be used in subsequent functional assays.
Effect of Smad7 on CB hematopoietic repopulating cell capacity
Previous studies using retroviral gene marking have determined that the cells within the Linpopulation that engraft the BM of NOD/SCID mice with differentiated myeloid and lymphoid progeny, termed SRC, are distinct fromthe less primitive hematopoietic progenitors detected in the in vitro CFU assay 31 , 48 . To evaluate whether Smad7 plays a role in regulating the human multilineage repopulating cells detected in this assay, sublethally irradiated NOD/SCID mice were transplanted with equivalent numbers of transduced Smad7 and Vector Lin-cells. Mice were sacrificed 5-8 weeks post-transplant for analysis of human hematopoietic reconstitution by flow cytometric analysis of the bone marrow (BM) using the human specific CD45 pan leukocyte marker (Fig 3a,i) , and those human cells expressing the transgene were detected by GFP fluorescence as shown (Fig 3a,ii) . From 5 independent CB samples transplanted into 13 mice, the level of human engraftment did not differ significantly between SRC transduced with Smad7 compared to Vector alone (Fig 3b) . In addition, the fraction of gene-marked (GFP+) human (CD45+) cells engrafting the NOD/SCID mouse was similar under Vector and Smad7 treatments (Fig 3c) suggesting that expression of Smad7 did not alter the level of hematopoietic chimerism. Since mice were transplanted with similar numbers of Vector or Smad7 transduced cells, this data suggests that overexpression of Smad7 did not result in increased expansion or proliferation of SRC.
Smad7 alters the developmental capacity of human hematopoietic repopulating cells
When Lin-populations containing SRC engraft the BM of NOD/SCID mice, these primitive cells divide and differentiate to give rise to committed cells of multiple hematopoietic lineages, in a distinctive lineages were examined in combination with CD45 and GFP expression, to assess the contribution of GFP+ cells to each of these hematopoietic lineages. In a representative experiment (Fig 3a) , Vector transduced SRC gave rise to committed cells with a typical pattern of engraftment 42 , where the majority of hematopoietic cells within the graft expressed the B-lymphoid marker CD19 (Fig 3a, iii) and a smaller population of cells expressed the pan-myeloid marker CD33 (Fig 3a, iv) . However, reconstitution of Smad7-SRC demonstrated equal lymphoid to myeloid graft composition. Overall, in 13 mice from 5 independent CB samples, a shift from the lymphoid (CD19+ cells) to myeloid (CD33+ cells) arm of the hematopoietic system was observed, representing 20% of the bulk GFP+ population derived from Smad7 SRC(Vector 73.2 : 26.3%, vs. Smad7 53.0 : 44.9%, lymphoid : myeloid progeny, p < 0.01, Fig 3a, iii and iv). The shift toward myeloid cells was apparent only in the GFP+ fraction of cells derived from the Smad7 transduced SRC (Fig 3d, i) . Acting as an internal control, the GFP-fraction of Smad7 cells, presumably not expressing the Smad7 transgene, displayed an engraftment pattern indistinguishable from the GFP-Vector transduced cells (Fig 3d, ii) . Since this lineage shift occurs only in GFP+ Smad7 cells, we suggest that Smad7 overexpression affects the development from multipotent SRC to differentiated progeny.
To address any potential variability between independent primary human CB samples, the percentages of lymphoid and myeloid cells were analyzed from paired mice transplanted with SRC from 5 separate CB samples (Fig 3f) . In all 5 CB samples, the engraftment pattern demonstrates a shift towards increased myeloid composition in Smad7 GFP+ cells. Despite the changes in lymphoid and myeloid contributions to the human hematopoietic graft, the proportion of primitive CD34+ cells was not altered in For personal use only. at PENN STATE UNIVERSITY on March 1, 2013. bloodjournal.hematologylibrary.org From Smad7 mice, regardless of GFP expression (Fig 3d) , suggesting that Smad7 alters the lineage commitment decision during hematopoiesis, but does not alter the total levels of differentiation or cellular expansion. hematopoietic cell subset, both present within the same Lin-population 49 . In 18 mice from 4 CB samples, transplanted Smad7-transduced Lin-cells gave rise to a lymphoid/myeloid pattern of engraftment indistinguishable from Vector control cells, in both the GFP+ (Fig 3e i) and GFP-subfractions (Fig 3e ii) , suggesting that Smad7 does not alter the myeloid-lymphoid repopulating function of STR hematopoietic cells, in contrast to the LTR-derived reconstitution observed in NOD/SCID recipients. We suggest that Smad7 acts on the LTR cells, which contain bipotent myeloid and lymphoid precursors.
Smad7 only affects in vivo reconstitution
Smad7 does not alter hematopoietic maturation subsequent to lineage commitment
To determine if the increase in myeloid cells, and decrease in lymphoid cells, is due to impaired development of myeloid cells, and hence accumulation of primitive blast-like myeloid cells, progression down the myeloid lineage was examined in greater detail by flow cytometric analysis of NOD/SCID mice engrafted from a representative CB sample (Fig 4a) . Bipotent granulocyte/monocyte precursors (CD33+CD15-), as well as mature monocytic and granulocytic progeny determined by the expression of Fig 4b, c) , and was reproducible in all independent CB samples examined. These results suggest that Smad7 does not block progression of uncommitted lymphoid cells toward the B-cell lineage prior to CD19 acquisition, but instead reduces the frequency of lymphoid cell fate commitment decisions prior to CD10 acquisition during SRC differentiation into lineage-restricted progeny.
Mice engrafted with Smad7 SRC demonstrate an increased frequency of functional myeloid progenitors
Our data suggest that mice engrafted with Smad7 SRC give rise to a greater proportion of committed myeloid cells compared to Vector SRC, based on expression of myeloid cell surface markers.
To determine if Smad7 also affects the frequency of functional myeloid progenitors, primitive CD34+ cells fractionated on GFP expression were isolated from the BM of engrafted mice by FACS (Fig 5a) . Aliquots of 5000 selected CD34+GFP+ or CD34+GFP-cells were placed into clonogenic progenitor assays to detect suggesting that Smad7 did not alter the process of myeloid maturation. Figure 5c summarizes the CFU-SRC capacity of Vector compared to Smad7 GFP+ cells. In 4 out of 5 experiments, mice transplanted with Smad7 SRC gave rise to more CFU-SRC per 5000 CD34+GFP+ cells than did Vector SRC from the same CB sample (average 4.6-fold increase). On average, Smad7 SRC gave rise to 41 GFP+ CFU-SRC, compared to only 18 CFU-SRC from the corresponding Vector control. Similar to phenotypic data, the increased frequency of CFU-SRC was apparent only in GFP+ Smad7 cells, as demonstrated by similar frequencies of GFP-Smad7 and Vector CFU-SRC, suggesting the effect is specific to overexpression of the Smad7 transgene (Fig 5c, inset) . Both Vector and Smad7 transduced cell populations gave rise to the full distribution of erythroid and myeloid CFU-SRC types at approximately equal proportions, both in the GFP+ population (Fig 5d) as well as the GFP-population (Fig 5d, inset) , suggesting that while Smad7 may influence the frequency of myeloid progenitors, Smad7 does not alter subsequent maturation of committed myeloid colony types.
Potential gene targets of Smad7 in primitive human hematopoietic cells
Downstream gene regulation by Smad7 has not been characterized in primitive human hematopoietic cells.
Given the effects of Smad7 on repopulating cells, we isolated primitive Smad7 transduced hematopoietic cells (CD34+SMAD7-GFP+) and compared their gene expression profile to similar cells transduced with vector alone (CD34+Vector-GFP+). Genes associated with the TGF-superfamily, including all known human Smads, were analyzed for differential regulation upon Smad-7 overexpression (Fig 6A) . With the exception of Smad7 (retrovirally transduced into the cells), Smads 1-9 were not regulated, suggesting the effects of Smad7 overexpression do not alter transcriptional regulation of other related SMAD genes. 
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Activation (SARA) were downregulated in response to Smad7 overexpression. Furthermore, consistent with our in vivo effects of Smad7 on cell fate of repopulating cells, specific genes involved in supporting myeloid lineages were upregulated, whereas other genes related to lymphoid differentiation were downregulated (Fig 6B) . Recently, putative downstream targets of the TGF-/BMP pathway have been identified 50 . Of these candidates, overexpression of SMAD7 in primitive human hematopoietic cells is capable of upregulating Insulin Growth Factor Binding Protein-5 (Igfbp5) whereas other recently reported targets were not regulated by SMAD7 (Fig 6C) , illustrating the specificity of SMAD7 and its cell specific effects. Taken together, these analyses provide new insights into potential Smad pathway related gene targets and mechanism of Smad7 to alter cell fate of primitive human hematopoieitc cells.
For
Discussion
It is well documented that numerous ligands of the TGF-superfamily are involved in various stages of hematopoietic regulation, both in humans and small animal models. However, the effects of downstream regulators of this signaling pathway by Smad effectors and inhibitors have yet to be evaluated.
Here, we examined the role of a TGF-superfamily inhibitor, Smad7, in primitive human hematopoiesis through retroviral modification of multipotent human hematopoietic cells with in vivo lymphoid and myeloid repopulating function (SRC). Surprisingly, overexpression of Smad7 in CB Lin-cells caused a lineage shift of SRC reconstitution toward myelopoiesis (Fig 3d, f) 42 . This observation suggests that Smad7 either alters the cell fate decisions of multipotent cells with myeloid and lymphoid differentiation capacity, or influences a subset of committed myeloid or lymphoid progeny to produce altered frequencies of mature cells. To determine at which stage of hematopoiesis Smad7 was acting, Smad7 transduced SRC were transplanted into NOD/SCID/ 2m -/-mice 40, 41 , that allow preferential engraftment of more mature STR hematopoietic progenitors, while the parental NOD/SCID strain only permits the engraftment of the more primitive LTR hematopoietic cells 49 . NOD/SCID/ 2m -/-mice transplanted with Smad7 transduced Lin-cells gave rise to myeloid/lymphoid progeny in a repopulation pattern indistinguishable from Vector control cells 6-8 weeks after transplant (Fig 3e) , suggesting that Smad7 has no effect on this more mature STR hematopoietic progenitor population. This suggests that Smad7 influences cell fate commitment decisions only in the most primitive human hematopoietic repopulating cells within the Lin-subfraction of CB MNCs.
Our study indicates that Smad7 did not block myeloid progression of SRC to cause an accumulation of early CD33+ myeloid blasts. Consistent with the phenotypic data supporting an increased production of normal myeloid cells from Smad7 SRC, we also observed an increase in the frequency of functional myeloid progenitors arising from the CD34+ cells within the BM of SRC-repopulated mice overexpressing Smad7 (Fig 5c) . Since the early stages of lymphoid commitment and B-lymphoid For personal use only. at PENN STATE UNIVERSITY on March 1, 2013. bloodjournal.hematologylibrary.org From maturation were not compromised in Smad7 SRC, and the decrease in committed lymphoid cells was due to a decrease in the frequency of lymphoid cell fate commitment decisions, our data suggests that Smad7 does not alter the behavior of cells once they have committed to a particular hematopoietic lineage. We suggest that Smad7 acts only to alter hematopoietic cell fate commitment decisions in the most primitive cells with in vivo lymphoid and myeloid differentiation potential. Since the NOD/SCID assays for human repopulating cells does not readily detect differentiation into the T-cell lineage, use of alternative recipients capable of supporting human T-lymphopoiesis will be required to determine whether SMAD7 effects lymphoid T-cell development.
This role for Smad7 in human SRC is similar in principle to observations of the role of Smad7 in Xenopus embryogenesis, where the ectopic expression of Smad7 in Xenopus embryos and animal pole explants was found to inhibit BMP-4 and Activin driven mesoderm formation, instead promoting/inducing neural cell fate decisions 27, 51 . There is no previous indication from the literature that Smad7 can alter cell fate commitment decisions in such a fashion in primary mammalian tissue, or outside of early embryonic development, thus identifying a novel role for Smad7 in multipotent human hematopoietic stem cell populations. Our hypothesis that Smad7 plays an important role in stem cell regulation is supported by the recent report that Smad7 expression is enhanced in murine multipotent HSC and pluripotent ESC populations, identified through oligonucleotide microarray analysis of genes preferentially expressed in various stem cell populations 28, 29 .
Only two other genes, both encoding leukemogenic transcription factors [52] [53] [54] have been shown to alter the hematopoietic balance from committed lymphoid to myeloid progeny in mice repopulated with retrovirally transduced human SRC. Retroviral mediated overexpression of HoxA10 in SRC gave rise to an engraftment pattern with increased myeloid and decreased lymphoid graft contribution, coupled with an absence of in vitro erythroid CFU and an increase in the frequency of SRC-derived blast-CFU incapable of proper myeloid differentiation 55 . In our study, the myeloid differentiation capacity of cells arising from Since Ikaros is believed to be an essential transcription factor for regulating the proliferation and differentiation of cells within the T and B lymphoid lineages 54 , Ik6 overexpression was proposed to cause an inhibition of B-cell development, thus leading to the development of a relative increase in the proportion of committed myeloid cells 56 . As the clonogenic capacity of myeloid CFU-SRC was increased with Smad7 overexpression, it seems unlikely that Smad7 operates upstream of genes responsible for regulating committed lymphoid lineages, but rather acts in a novel manner to modulate the expression of genes involved in the earliest hematopoietic lineage commitment decisions. The mechanism by which Smad7 achieves this effect on cell fate decisions remains to be elucidated and these efforts will be facilitated by preliminary microarray data that identifies regulated genes in response to Smad7 overexpression. 
